Background
==========

Recognising cognitive impairment is of growing importance, as the worldwide prevalence of dementia is increasing \[[@B1]\]. In elderly medical inpatients this is particularly important, as cognitive impairment is a poor prognostic factor and an independent predictor of mortality \[[@B2]-[@B4]\]. Furthermore, cognitive impairment may be associated with undetected medical comorbidities, mental incapacity and risk of accidents at home after discharge \[[@B5]-[@B8]\]. In hospitals, patients with cognitive impairment may have communication difficulties when specifying their complaints or in the comprehension of discharge information \[[@B9]\].

Cognitive impairment is often undetected during an admission in general hospital settings \[[@B10]-[@B14]\]. In primary care, cognitive impairment is often underdiagnosed as well \[[@B15]-[@B19]\]. This has highlighted the need for cognitive screening to improve detection. In community-based studies, screening with subjective memory complaints (SMCs) have been tried with varying results, possibly due to large inconsistencies in definition of SMCs \[[@B20],[@B21]\]. In hospital settings, delirium guidelines have recommended screening by performing cognitive tests on all elderly patients admitted to hospital \[[@B22]\]. Our aim was to assess the need for such a screening by performing cognitive tests in a general hospital population and compare the results with SMCs and recognition from healthcare professionals. To determine the risk accompanying cognitive impairment we also aimed to study its association with mortality.

Methods
=======

Setting
-------

The study was carried out at the wards of the Department of General Internal Medicine at the University Hospital MAS, in Malmö, Sweden. Data was collected from October 2009 through June 2010. At the time, the hospital was a 700-bed teaching hospital, providing healthcare to the community of Malmö and its surrounding areas. The hospital is now part of the larger Skåne University Hospital.

The Department of General Internal Medicine consisted of four wards with a similar general medical profile. The average length of stay was 6.4 days. Most patients (90-95%) were admitted through the hospital's Emergency Department (ED), the rest were directly referred via their GPs.

The study included only the hospital's general internal medicine wards; all medical departments with a higher degree of specialisation (Endocrinology, Angiology, Haematology, Nephrology, Gastroenterology, Rheumatology, Cardiology, the Department of Infectious Diseases and the Department of Pulmonary Diseases) were excluded. At the general internal medicine wards, patients tended to be older or to have multiple comorbidities to a larger extent than at the more specialised wards. The hospital's bed manager, unaware of our study, designated the patients to their wards.

Whether at the ED or directly at the wards, a staff physician examined all patients on arrival, documenting presenting complaint, past medical history, drug history and examination findings. A nurse also assessed all patients when arriving at the wards. This included standardised estimates of the risk of falls and pressure sores, using the Downton Fall Risk Index and the Modified Norton Scale, respectively \[[@B23],[@B24]\]. These procedures were done according to hospital policy.

Patients
--------

Eligible patients were 60 years or older, residing in the city of Malmö and not living in a nursing home. Occasionally, eligible patients were not available to enter the study, e.g. if patients were put in isolation due to norovirus infection.

Study personnel approached eligible and available patients on the first or second day of their stay to determine appropriateness for cognitive testing. For example, patients with terminal disease or severe aphasia were considered inappropriate. Patients were considered inappropriate at admission if a possibly reversible condition was present, such as severe delirium (incoherent speech, inability to focus attention) and/or abnormal laboratory values (Haemoglobin \< 100 g/L, temperature \> 38°C, C-Reactive Protein \> 50 mg/L, abnormal electrolytes). These patients were assessed continuously and, if the condition resolved, they were subsequently included.

Eligible, available and appropriate patients were approached regarding consent. All included patients gave their written informed consent. If cognitive tests disclosed significant cognitive impairment, written consent from an informant was collected as well. This procedure was approved by the regional ethics committee at Lund University.

Measurements
------------

Three experienced research assistants (two certified occupational therapists and one registered nurse) carried out the measurements at the ward, in a private and calm environment, between 8 am and 4 pm.

Interviews and comorbidity
--------------------------

Interviews were held with patients concerning living situation, family, education and access to home care. Presenting complaints noted in the charts on admission were recorded. Past medical history was extracted from the hospital's charts, all conditions noted during the current or three preceding admissions were recorded. Frequent conditions were classified as absent/present. The list of current medications in the medical records was examined on admission and the cumulative number of drugs was noted. We used Charlson comorbidity index to obtain a standardised estimate of comorbidity \[[@B25]\].

Cognitive tests
---------------

The MMSE, (Mini-Mental State Examination) and the CDT (Clock-Drawing Test) were employed \[[@B26],[@B27]\]. The MMSE is scored from 0--30, with 0 points representing maximum cognitive impairment. As a cut-off, ≤ 23 points was used. In the CDT, the patients were asked to draw a clock on a sheet of paper and add the hands of the clock showing "ten past eleven". The CDT was scored from 0 to 5 according to Shulman, where 0 points denote maximum cognitive impairment and 5 points a perfect clock \[[@B27]\]. Any scoring uncertainties were discussed within the group until a consensus was reached. As a cut-off, ≤ 3 points were used. Previous studies have described a correlation between MMSE and CDT scores, with a mean correlation coefficient of 0.61, and that combining the tests gives higher diagnostic accuracy for neurocognitive disorders \[[@B27]\]. The CDT is also less affected by depression than the MMSE \[[@B28]\].

QoL-AD
------

The Quality of Life in Alzheimer's Disease (QoL-AD) scale was employed \[[@B29]\]. The QoL-AD contains 13 items (Physical health, Energy, Mood, Living situation, Memory, Family, Marriage, Friends, Self as a whole, Ability to do chores around the house, Ability to do things for fun, Money and Life as a whole). The items are rated from 1 to 4 where 1 represents poor, 2 fair, 3 good and 4 excellent. The rating can be done by patients and/or proxies.

Subjective memory complaints (SMCs)
-----------------------------------

SMCs were determined in two ways. Firstly, a direct yes/no question was asked: 'Do you think that your memory has gotten worse lately?' Secondly, the memory item of the QoL-AD scale was used. This item was dichotomised, with a score of 1--2 denoting subjective memory complaints and 3--4 no impairment.

Informants
----------

If available at the hospital, informants rated the patients' quality of life with the QoL-AD scale. As for the patients, the memory item was dichotomised and a score of 1 or 2 denoted cognitive impairment. This was done separately from the patients' ratings.

Recognition by staff physicians
-------------------------------

The staff physicians' admission notes from the first day were reviewed. Any notation of neurocognitive disorders (dementia, delirium or MCI -- mild cognitive impairment) or current symptoms (disorientation, memory impairment, confusion, irrational behaviour etc.) was considered as recognition of cognitive impairment.

Recognition by staff nurses
---------------------------

The nurses' admission notes were examined. The Downton Fall Risk Index comprises a yes/no item entitled "cognitive impairment" \[[@B23]\]. The Modified Norton Scale includes the item "mental condition", that is scored from 1--4 (with 1 representing "no contact", 2 "cannot answer adequately", 3 "occasionally confused" and 4 "fully oriented") \[[@B24]\]. Scores other than "no cognitive impairment" or "fully oriented" on any of the scales was considered recognition of cognitive impairment.

Intervention status
-------------------

The included patients were also taking part in a prospective intervention study aiming to reduce hospital readmissions. Interventions included a pharmacist's medication review and a changed discharge routine. For the present study, only intervention status (control or intervention) was recorded to rule out the possibility of this confounding the results.

Statistical method
------------------

Patients were divided into three groups according to their results on cognitive tests, with 0, 1 or 2 abnormal test results, where patients with 1 abnormal result could have a low score either on the MMSE or on the CDT. All other baseline variables were compared between the three groups. In the primary comparison, ANOVA and chi-square tests were used where appropriate. In secondary analyses we did pairwise comparisons between groups with Bonferroni correction for multiple comparisons. The correlation between MMSE and CDT scores was determined using Spearman's rho.

Survival analysis
-----------------

Bivariate Cox proportional hazards regressions were done separately for demographic variables, comorbidity variables and cognitive tests, adjusting for age and sex where applicable. The 'number of abnormal cognitive tests' variable was dummy-coded to compare 1 abnormal test vs 0 and 2 abnormal tests vs 0. The assumption of proportional hazards (that relative risk is not time-dependent) was tested using log-log plots and time-interaction tests, no violations of the assumption were found.

For the multivariable analysis a stepwise approach was carried out, using a backwards method with p \>0.051 as the threshold for removal. Starting the stepwise model with all variables or only the ones with a bivariate p value of \<0.25 resulted in the same final model. Exclusion of categorical variables with small cells (neurocognitive disorder) did not affect the final model. Testing for multiple collinearity revealed a moderate correlation between 'Charlson comorbidity index' and 'number of drugs' (Spearman's rho, r = .46), exclusion of the latter did not affect the final model. For each step our model was controlled and fit the data adequately.

All calculations were done using the SPSS software (SPSS version 19.0, SPSS inc. Chicago Illinois). A two-sided p value of \< 0.05 was considered significant.

Results
=======

Patients
--------

During the study period, 612 patients were admitted in total. Of these, 98 were not eligible and 89 patients were excluded because of hospital-related reasons. In 121 patients, cognitive testing was considered inappropriate. At the point of consent, 69 patients declined participation. After consent, 35 patients were excluded, due to issues occurring between consent and cognitive testing (see Figure [1](#F1){ref-type="fig"}). Thus, the study population consisted of 200 patients. There were no differences between the included patients, excluded patients or patients not giving consent with regard to age (ANOVA, *F* (2, 609) = 1.49, *p* = 0.23) or sex (χ^2^ (2, *N* = 612) = 3.88, *p* = 0.14).

![Patient flow showing exclusion criteria.](1471-2318-12-47-1){#F1}

Results on cognitive tests
--------------------------

All 200 patients completed the MMSE and 198 patients completed the CDT. In total, 55 patients (28%) had 0 abnormal test results, 68 (34%) had 1 abnormal result (45 CDT and 23 MMSE) and 77 (39%) had abnormal results on both the MMSE and the CDT.

Baseline measurements
---------------------

Patients with 2 abnormal test results were older than those with 0 abnormal tests. Patients with 1 .abnormal test result were living alone to a larger extent than those with 0 abnormal test results. Regarding presenting complaints, shortness of breath was the most prevalent, accounting for nearly a third of admissions (32% in total). Falls were more frequent in the group with 2 abnormal cognitive tests than in the group with 1 abnormal test.

The mean scores on the MMSE and the CDT differed significantly between all three groups. The results on the CDT correlated moderately with the results on the MMSE (Spearman's rho, r(198) = .50, p \< .001). Baseline measurements are shown in Table [1](#T1){ref-type="table"}.

###### 

Baseline characteristics

                              **Abnormal cognitive test results**   **Statistic**   **p value**   **Significant post-hoc differences\***                   
  -------------------------- ------------------------------------- --------------- ------------- ---------------------------------------- ---------------- ---------
  Age, mean(SD)                            80.6(8.8)                  83.1(8.5)      85.8(6.6)               F(2, 197) = 7.45                  0.001           b
  Male sex                                    46%                        30%            31%             χ^2^(2, *N* = 200) = 3.64               0.16          \-
  Living alone                                54%                        78%            68%             χ^2^(2, *N* = 200) = 6.63               0.04           a
  Home care                                   44%                        61%            62%             χ^2^(2, *N* = 200) = 4.51               0.11          \-
  Education ≤8 years                          46%                        61%            54%             χ^2^(2, *N* = 188) = 2.45               0.29          \-
  In intervention                             50%                        53%            47%             χ^2^(2, *N* = 200) = 0.56               0.76          \-
  Presenting complaint                                                                                                                                     
  Shortness of breath                         37%                        33%            26%             χ^2^(2, *N* = 200) = 2.25               0.33          \-
  Fall                                        9%                         3%             17%             χ^2^(2, *N* = 200) = 7.87               0.02           c
  Chest pain                                  9%                         9%             8%              χ^2^(2, *N* = 200) = 0.08               0.96          \-
  Infection                                   15%                        9%             4%              χ^2^(2, *N* = 200) = 4.69               0.10          \-
  General condition                           3%                         16%            9%              χ^2^(2, *N* = 200) = 6.61               0.04           a
  Pain                                        7%                         2%             7%                  FET(0vs1) *N* =123                0.17^†^         \-
  Neurological symptoms                       2%                         10%            5%                  FET(0vs1) *N* =123                0.07^†^         \-
  Psychiatric                                 0%                         3%             9%                  FET(0vs2) *N* =132                0.04^†^         \-
  Laboratory value                            9%                         6%             5%                  FET(0vs2) *N* =132                0.49^†^         \-
  Lower extremity symptoms                    6%                         7%             4%                  FET(1vs2) *N* =145                0.48^†^         \-
  Other                                       2%                         2%             7%                  FET(1vs2) *N* =145                0.21^†^         \-
  MMSE, mean(SD)                           26.5(2.0)                  24.3(2.5)      18.9(3.2)              F(2, 197) = 143.62             (\<0.001) ^††^   a, b, c
  CDT, mean(SD)                            4.7(0.5)                   3.4(1.1)       2.4(0.9)               F(2, 195) = 109.62             (\<0.001) ^††^   a, b, c

Baseline characteristics of the groups with 0, 1 and 2 abnormal cognitive tests.

\* Significant differences (p \< 0.05) after Bonferroni correction:

a = between 0 vs 1 abnormal cognitive test.

b = between 0 vs 2 abnormal cognitive tests.

c = between 1 vs 2 abnormal cognitive tests.

^†^ = Fischer's exact test (FET) was used due to expected counts \< 5. All three pairs (0vs1, 0vs2 and 1vs2) were compared, the comparisons with the lowest p values are displayed.

^††^ = The p values of cognitive tests are in brackets as they were the criteria for the division.

Past medical history
--------------------

Reviewing patients' medical records showed no differences in prevalence of specific diagnoses between the three groups. Neither were there any differences in mean cumulative number of drugs in charts or in Charlson comorbidity index. In total, 14 patients had a registered ICD-10 diagnose of neurocognitive disorder (5 with Alzheimer's disease, 4 with unspecified dementia, 4 with mild cognitive impairment and 1 with Parkinson's disease with dementia). Of these 14 patients, 3 were found in the group with 0 abnormal test, 2 in the group with 1 abnormal test and 9 in the group with 2 abnormal tests, see Table [2](#T2){ref-type="table"}.

###### 

Past medical history

                                          **Abnormal cognitive test results**   **Statistic**   **p value**   **Significant post-hoc differences**         
  -------------------------------------- ------------------------------------- --------------- ------------- -------------------------------------- ------ ----
  Ischemic heart disease                                  43%                        34%            27%            χ^2^(2, *N* = 200) = 3.05         0.22   \-
  Arrhythmia                                              39%                        37%            30%            χ^2^(2, *N* = 200) = 1.45         0.49   \-
  Heart failure                                           24%                        30%            29%            χ^2^(2, *N* = 200) = 0.81         0.67   \-
  Hypertension                                            47%                        52%            47%            χ^2^(2, *N* = 200) = 0.37         0.83   \-
  COPD                                                    26%                        19%            16%            χ^2^(2, *N* = 200) = 2.00         0.37   \-
  Gastrointestinal disease                                22%                        18%            13%            χ^2^(2, *N* = 200) = 1.80         0.41   \-
  Stroke/TIA                                              19%                        21%            21%            χ^2^(2, *N* = 200) = 0.16         0.92   \-
  Diabetes                                                22%                        29%            18%            χ^2^(2, *N* = 200) = 2.63         0.27   \-
  Cancer, nonskin                                         31%                        30%            25%            χ^2^(2, *N* = 200) = 0.72         0.70   \-
  Neurocognitive disorder                                 6%                         4%             12%            χ^2^(2, *N* = 200) = 3.21         0.22   \-
  Drugs in chart, mean(SD)                             7.1(3.8)                   7.6(4.0)       6.6(3.7)               F(2, 197) = 1.20             0.30   \-
  Charlson comorbidity index, mean(SD)                 2.3(1.7)                   2.4(1.4)       2.1(1.5)               F(2, 197) = 0.77             0.47   \-

Past medical history of the three groups. TIA = transient ischemic attack. COPD = chronic obstructive pulmonary disorder.

Subjective memory complaints and recognition
--------------------------------------------

When using the yes/no question, prevalence of SMCs was similar in all three groups, with more than two thirds of patients experiencing SMCs. When using the QoL-AD to measure SMCs, no significant differences were found between groups. Informants (n = 141) classified 46/60 (77%) of the patients with 2 abnormal tests as cognitively impaired. This was significantly more than in the other groups, in which 9/37(24%) (0 abnormal tests) and 17/44 (39%) (1 abnormal test) were classified as cognitively impaired. Staff physicians recognised 44% of the patients with 2 abnormal tests as cognitively impaired. In the same group, staff nurses recognised 64%. Neither physicians nor nurses recognised cognitive impairment in the group of patients with 1 abnormal test to a larger extent than in the group with 0 abnormal tests (Table [3](#T3){ref-type="table"}).

###### 

Recognition of cognitive impairment

                                                         **Abnormal cognitive test results**   **Statistic**   **p value**   **Significant post-hoc differences\***            
  ----------------------------------------------------- ------------------------------------- --------------- ------------- ---------------------------------------- --------- ------
  Subjective memory complaints yes/no                                    67%                        73%            65%             χ^2^(2, *N* = 200) = 1.45           0.48      \-
  Subjective memory complaints QoL-AD                                    48%                        55%            59%             χ^2^(2, *N* = 200) = 1.74           0.42      \-
  Cognitive impairment recognised by informant QoL-AD                    24%                        39%            77%             χ^2^(2, *N* = 141) = 29.05         \<0.001    b
  Cognitive impairment recognised by staff physician                     9%                         12%            44%             χ^2^(2, *N* = 200) = 29.84         \<0.001   b, c
  Cognitive impairment recognised by staff nurse                         15%                        12%            64%             χ^2^(2, *N* = 200) = 55.44         \<0.001   b, c

Recognition of cognitive impairment.

\* Significant differences (p \< 0.05) after Bonferroni correction:

a = between 0 vs 1 abnormal cognitive test.

b = between 0 vs 2 abnormal cognitive tests.

c = between 1 vs 2 abnormal cognitive tests.

QoL-AD = Quality of life in Alzheimer's disease.

Survival analysis
-----------------

After 12 months, 63 patients (32%) in total were deceased with a median survival of 96 days (interquartile range 32--222). In the group with 0 abnormal tests, 8/55 (14%) were deceased, compared to 25/68 (37%) in the group with 1 abnormal test and 30/77(39%) in the group with 2 abnormal tests.

In bivariate Cox proportional hazards analysis four variables were significant predictors of mortality; home care, abnormal cognitive tests, heart failure and Charlson comorbidity index. The stepwise selection procedure resulted in a final, multivariable model in which male sex, home care, abnormal cognitive tests, and higher Charlson comorbidity scores predicted mortality. The hazard ratios (95% CI) of cognitive tests were similar for 1 and 2 abnormal tests vs 0, with 2.86 (1.28-6.39) and 3.39 (1.54-7.45), respectively, see Table [4](#T4){ref-type="table"}. Kaplan-Meier estimates of survival with the number of cognitive tests as independent variable are shown in Figure [2](#F2){ref-type="fig"}.

###### 

Cox proportional hazards

                                                    **Bivariate models HR (95% CI)**   **p value**   **Multivariable model HR (95% CI)**   **p value**
  ------------------------------------------------ ---------------------------------- ------------- ------------------------------------- -------------
  Age (years)                                               1.03 (0.99-1.06)              0.11                                                   
  Male sex                                                  1.50 (0.91-2.47)              0.11                1.75 (1.02-2.93)                0.03
  Living alone                                              1.12 (0.63-1.98)              0.70                                                   
  Home care                                                 1.96 (1.10-3.47)              0.02                1.82 (1.05-3.14)                0.03
  Intervention status (0 = control, 1 = interv.)            1.03 (0.62-1.69)              0.92                                                   
  Education ≤ 8 years                                       1.03 (0.62-1.74)              0.90                                                   
  Ischemic heart disease                                    1.07 (0.64-1.81)              0.79                                                   
  Arrhythmia                                                1.21 (0.72-2.01)              0.47                                                   
  Heart failure                                             1.98 (1.19-3.29)              0.01                                                   
  Hypertension                                              0.96 (0.58-1.97)              0.87                                                   
  COPD                                                      1.18 (0.62-2.24)              0.62                                                   
  Gastrointestinal disease                                  1.30 (0.71-2.40)              0.40                                                   
  Stroke/TIA                                                0.96 (0.51-1.82)              0.91                                                   
  Cancer, nonskin                                           1.44 (0.86-2.43)              0.17                                                   
  Diabetes                                                  1.04 (0.55-2.00)              0.90                                                   
  Neurocognitive disorder                                   1.39 (0.60-3.23)              0.44                                                   
  Drugs (total number)                                      1.05 (0.98-1.11)              0.15                                                   
  Charlson index (points)                                   1.35 (1.16-1.58)             \<0.001              1.31 (1.12-1.54)                0.001
  Cognitive tests                                                                                                                                
  1 abnormal vs 0                                           2.98 (1.33-6.65)              0.008               2.86 (1.28-6.39)                0.01
  2 abnormal vs 0                                           3.29 (1.47-7.45)              0.004               3.39 (1.54-7.45)                0.002

Cox proportional hazards. Bivariate models are adjusted for age and sex where applicable. All categorical variables are coded 0 = no, 1 = yes unless indicated otherwise.

![**Kaplan-Meier estimates of 12-month survival for the three groups with 0, 1 and 2 abnormal cognitive test results.**Log rank χ^2^(df = 2, *N* = 200) = 9.7, p = 0.008.](1471-2318-12-47-2){#F2}

Discussion
==========

In this study we used two cognitive tests to show that cognitive impairment was common in medical inpatients, with 73% of patients having at least one abnormal test result during hospitalisation. By using a multivariable Cox proportional hazards model, we showed that cognitive impairment was associated with a three-fold increase in 12-month mortality.

We divided the patients into three groups according to their results on cognitive tests (with 0, 1 and 2 abnormal tests). Demographic data, presenting complaints and comorbidity showed only subtle differences between the three groups. In terms of recognition, the hospital staff did not recognise cognitive impairment in the group with 1 abnormal test any more than in the group without impairment. This is alarming, as the increase in mortality risk of this group was substantial and similar to that of the group with 2 abnormal tests. To improve detection of cognitive impairment, our study suggests that subjective memory complaints are too unspecific to be used effectively, but that informants should be considered as valuable assets.

Our regression model did not retain variables that one would expect to be significant predictors of mortality, such as age or certain comorbidities, e.g. cancer. Regarding age, this could be due to the designation of patients to different departments at the hospital. At general internal medicine wards, patients tended to be either very old or slightly younger but with multiple comorbidities, for example, a 65-year old with a heart attack would typically be transferred from the ER to the cardiology department but a 65-year old with diabetes, hepatic failure, obesity, a neurologic disease and an infection would more likely be transferred to a general internal medicine ward. This selection could have affected the impact of age on mortality in our study population. Regarding comorbidities, these were coded merely as absent/present, there was no severity ranking or temporal perspective. Therefore, a patient who had had surgery 30 years ago for cancer of the colon was not distinguished from a patient with present metastatic disease. This is of course not a proper representation of the clinical situation. However, the inclusion of Charlson comorbidity index, a very stable and highly significant comorbidity variable, in our model did not affect the finding that cognitive impairment independently predicted mortality.

Studying nurses' and physicians' recognition at admission only may seem unfair to regular staff, as impairment could have been discovered later on. However, for ethical reasons, regular staff was informed promptly when cognitive impairment was disclosed in a patient, thus prohibiting studies of the staff's recognition further along the admission. Changes in cognition could have occurred between admission and administration of cognitive tests, for example delirium resolving quickly or incident delirium occurring between admissions and testing. However, our cognitive tests were performed when laboratory values were within an acceptable range and patients were generally in a better state when tested than upon admission. This indicates that changes of cognition were likely to have been to the better, thus favouring the staff's recognition on admission. The physicians and the nurses were aware of the study and it is likely that they were more vigilant towards cognitive symptoms than in regular conditions. Furthermore, we used the most generous cut-offs possible to represent recognition. Taken together, it is unlikely that the recognition rates by hospital staff have been underrated.

Representativity also needs to be addressed, as many patients were not included. Patients excluded for hospital-related reasons (with unknown cognitive status) were fewer (n = 89) than patients excluded due to disease-related conditions (n =121). The latter could be assumed more cognitively impaired, given the exclusion criteria (severe delirium, terminal disease, aphasia etc.). This would give a bias towards including the healthier part of the population. This notion is also supported by the fact that all included patients managed to fulfil the interview and the MMSE. Thus, it is unlikely that the prevalence of cognitive impairment is overrated.

We did not aim to diagnose dementia or delirium but rather to study cognitive impairment in a broader sense including its recognition and consequences in terms of mortality. To some extent, we tried to exclude patients with delirium but most likely patients fulfilling delirium criteria were included in the study. However, our findings imply that acknowledging cognitive impairment is important in medical inpatients regardless of its duration.

The main strengths of our study are its simplicity and the possibility to apply the findings in a clinical setting. We used two widely employed cognitive tests, taking approximately 15 minutes to administer. These were performed in a standardised way, much similar to that of clinical routine. We used an easily applicable approach with 0, 1 or 2 abnormal test results to make a crude estimation of cognitive impairment. Despite this simple approach, our estimate of cognitive impairment was a significant predictor of mortality in a clinical material of 200 patients with multiple diseases. Furthermore, we used simple questions and measures already applied in hospital routine to study the recognition of cognitive impairment from the patients' perspective as well as from informants and different healthcare professionals.

Conclusions
===========

Our study highlights the need for improved detection of cognitive impairment in hospitals, by confirming that cognitive impairment is often underdiagnosed and associated with an increased risk of mortality. Given the high prevalence of cognitive impairment, a more active approach to identify these patients is needed. Whether mandatory cognitive tests are to be applied in all medical inpatients should be a matter of discussion and further study. It is however clear that undetected cognitive impairment is far too common in medical inpatients and recognition rates need to improve.
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